Let's take a look at VBI 9-rated stock AmerisourceBergen, a pharmaceutical sourcing and distribution company that yields 2% as of this writing. We like AmerisourceBergen's dividend growth story, strong free cash flow generation, guidance raise, and relatively low net debt load. We'll also cover AmerisourceBergen's downside risks as well as its upside potential. Shares appear undervalued as things stand today, with ABC trading below the low end of our fair value estimate range.
This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!